Lisata Therapeutics Inc./$LSTA
1D1W1MYTD1Y5YMAX
Capital at risk
About Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
- Ticker
- $LSTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 21
- Headquarters
- Basking Ridge, United States
- Website
- www.lisata.com
LSTA Metrics
BasicAdvanced
$15M
-
-$1.64
0.88
-
Price and volume
Market cap
$15M
Beta
0.88
52-week high
$5.07
52-week low
$0.99
Average daily volume
495K
Financial strength
Current ratio
3.687
Quick ratio
3.563
Profitability
EBITDA (TTM)
-16.362
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-14,621.00%
Operating margin (TTM)
-16,426.00%
Effective tax rate (TTM)
2.58%
Management effectiveness
Return on assets (TTM)
-56.74%
Return on equity (TTM)
-101.66%
Valuation
Price to revenue (TTM)
151.529
Price to book
1.88
Price to tangible book (TTM)
1.88
Price to free cash flow (TTM)
-1.23
Free cash flow yield (TTM)
-81.33%
Free cash flow per share (TTM)
-1.383
Growth
Revenue change (TTM)
-90.65%
Earnings per share change (TTM)
-26.48%
10-year revenue growth (CAGR)
-38.75%
3-year earnings per share growth (CAGR)
-39.70%
10-year earnings per share growth (CAGR)
-37.09%
Upcoming events
No upcoming events
LSTA News
AllArticlesVideos
Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Benzinga2 days ago
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
Proactive Investors2 days ago
Lisata Therapeutics moves forward with legal action following Kuva merger termination
Proactive Investors2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.